AstraZeneca announced on Monday that its vaccine was 79 percent effective in preventing symptomatic COVID-19 in Phase III U.S. testing with no safety concerns found.
The company said in a statement that the vaccine was also found to be 100 percent effective in preventing serious cases of the disease and hospitalizations.
AstraZeneca said it will submit the findings to the Food and Drug Administration in a bid for emergency use authorization in the U.S.
“Who do you know that others need to know?
We are always one conversation away from changing our lives, and Rich Bendis of BioHealth Innovations started the BioTalk podcast to connect the world of biohealth better.
In a world where medical science advances are growing at the fastest pace in human history, we can still run into a problem where the people who know each other don’t get connected to advance therapy, new medicine, or new approaches.”
Key Topics:
What is the goal of Biohealth Innovations (1:44)
How has the medical research changed as a result of COVID (3:24)
How was the COVID vaccine researched (8:06)
What made podcasting the right next step for BioHealth (10:22)
Who has benefited from the podcast (12:29)
Visit https://causepods.org/podcast/the-more-we-know-with-rich-bendis-of-the-biotalk-podcast/ to listen.
Wednesday, March 24, 2021
Are you a biohealth start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your feedback session with BHI EIRs on one of the following dates. Pre-registration is required; Sign up here tinyurl.com/EIRfeedback
WASHINGTON, MARCH 19, 2021 – This week, U.S. Senators Chris Coons (D-Del.) and Dick Durbin (D-Ill.), both members of the Senate Appropriations Committee and Senate Competitiveness Caucus, reintroduced the Innovation Centers Acceleration Act, a bill which would expand research and development (R&D), targeted to reach a broader portion of the country. The legislation would complement a nationwide effort to compete with China economically by placing renewed emphasis on sectors key to economic resiliency and productivity, including biomedical technology, advanced manufacturing, and more.
“We lost about nine months in time,” said Galen Robotics CEO Bruce Lichorowic.
Image: David Saunders (left) and Bruce Lichorowic are the co-founders of Baltimore-based medical robotics startup Galen Robotics. GALEN ROBOTICS
Richmond-based Phlow Corp. announced Thursday the launch of a coalition that will help ensure that children’s hospitals across the country receive key medications. The Virginia Commonwealth University-affiliated Children’s Hospital of Richmond is one of 11 founding hospital members.
Children’s Hospital Coalition (CHC) aims to provide certainty in availability and access to medicine and address supply chain issues. Citing a 2019 survey of 330 American hospitals — including 29 children’s hospitals — Phlow says that medicine shortages disproportionately and uniquely impact children’s hospitals. The company also says that the pandemic has further exposed the vulnerabilities of the supply chain.
Image: Dr. Eric Edwards, co-founder and CEO of Richmond-based Phlow Corp.
It is with immense gratitude and sincere best wishes that I announce National Center for Advancing Translational Sciences (NCATS) Director Christopher P. Austin, M.D. will be departing NIH. His last day will be April 15, 2021. After nearly a decade of bold leadership as the founding director of NCATS, Chris will become CEO-partner at Flagship Pioneering, a life science platforms company in Cambridge, Massachusetts.
Image: NCATS Director Christopher P. Austin, M.D.Daniel Soñé Photography, LLC
RICHMOND, Va., March 18, 2021 – Phlow Corp., a U.S.-based, public benefit corporation committed to a bold mission of providing every American with access to affordable, high-quality essential medicines, today joins in announcing the launch of a groundbreaking Children’s Hospital Coalition: Powered by PhlowTM (CHC). This first-in-kind coalition brings together some of the top children’s hospitals across the nation, in collaboration with Phlow, to provide certainty in availability and access for key medicines necessary to sustain life and conquer disease and to address the nation’s broken essential medicines supply chain.
Launching an innovative product or technology takes more than a good idea, and there are many actions startups can take to strengthen their offering and overall chance of success as they develop the latest innovations to bolster health security, including battling COVID-19. Over the last year, the global scientific community has proven critical to our collective ability to combat the pandemic, and BLUE KNIGHT™ offers a new way to build the kinds of partnerships needed to advance potentially life-saving technology during public health emergencies.
In March 2021, the Dutch government celebrates the start of Horizon Europe. Horizon Europe is the new European framework programme for research and innovation. During a series of online events, we will inform you about the possibilities within this large funding programme.
The National Contact Points from the Netherlands Enterprise Agency organise these events.
The series of events starts with an online kick-off event about the importance of Horizon Europe for the Netherlands. This event focusses on the policy aspects of the programme and is in Dutch. Find out more about the kick-off event (in Dutch).
